IID | Jotup

Managing the transition to central bank digital currency

Retrieved on:

Wednesday, February 14, 2024

Technical report, Regulation, Private sector, Aircraft, Interest, RTD, Policy, CES, Research Papers in Economics, A.2, The Economic Journal, RTK, International Settlement, F30, Next, A.6, Community business development corporation, A.7, UIP, American Economic Journal, National bank, Paper, Bank, Macroeconomics, Economy, Central bank, GSS, Capital, XF, Elasticity, Government, Competition, Credit, Social science, Volatility, Domestic, European, IH, Investment, A.13, SSRN, Intermediate, A.5, Section 2, AP, Probability, Review of Economic Dynamics, Foreign, Journal of Monetary Economics, Remuneration, Uncertainty, Medical classification, Bank of England, Shock, DF, Bank of Canada, ISSN, CIA, European Central Bank, Survival, RD, FH, KT, N B, Cuore, Monetary economics, Section 3, Welfare, Iteration, DSGE, Blessthefall, Reserve, Website, GBP, Calibration, RDC, Parameter, DCT, GDP, KF, Sokol, Rebelo, Figure, De Nederlandsche Bank, Parity, TFP, Depreciation, Total, BIS, Home, Section 4, Attitude, Acquisition, JEL, Cross, Household, FF, QT, Control, Swiss, Motion, ECB, M. A, GF, A.9, RT, Cattolica, Exercise, C.2, XH, Tax, Crowding, European Parliament, Literature, Reproduction, Political economy, Committee, Exp, E50, Uhlig, EUR, IID, Digital currency, Tourism, American Economic Review, Manuscript, AG, A.8, Research, F41, Friction, Public sector, PDF, U N, YH, Cryptocurrency

Key Points:

IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™

Retrieved on:

Wednesday, October 25, 2023

This includes syntactical (sequence) data, 3D structural data, unstructured scientific information (e.g., scientific literature), all integrated within a singular framework, the LENSai Knowledge Graph.

Key Points:

This includes syntactical (sequence) data, 3D structural data, unstructured scientific information (e.g., scientific literature), all integrated within a singular framework, the LENSai Knowledge Graph.
This breakthrough facilitates efficient data fusion, enabling a comprehensive analysis and interpretation of complex biological data.
Knowledge Graphs and LLMs have been recognized for their superior performance over conventional approaches in drug discovery.
For instance, for the important step of identifying drug targets, AI-powered language models have demonstrated superiority over even the most state-of-the-art approaches.

Akita Biosciences Launches to Pioneer Novel Intranasal Therapies

Retrieved on:

Tuesday, October 10, 2023

BOSTON and COLUMBUS, Ohio, Oct. 10, 2023 /PRNewswire/ -- Akita Biosciences, a biotechnology company focused on consumer health, is launching today with a mission to bring novel therapies to market. The company is developing pioneering science around the importance of the nasal cavity, both as a pathway for therapeutics and as a way to defend against illness. Akita Biosciences was founded based on research conducted at Brigham and Women's Hospital in Boston.

Key Points:

BOSTON and COLUMBUS, Ohio, Oct. 10, 2023 /PRNewswire/ -- Akita Biosciences , a biotechnology company focused on consumer health, is launching today with a mission to bring novel therapies to market.
Akita Biosciences was founded based on research conducted at Brigham and Women's Hospital in Boston.
Based on this research, "Akita Biosciences developed a radically simple approach that works with the natural defenses in the nose," said Alex Revelos, CEO.
Building on the commercial launch of Profi, Akita Biosciences expects to continue developing biomaterials to support a wide range wellness, drug delivery, and therapeutic applications.

ID Quantique's range of Quantum Random Number Generator (QRNG) chips are the first quantum-based RNGs's to receive NIST Entropy Source Validation (ESV) Certification on IID Track

Retrieved on:

Wednesday, September 20, 2023

Random number generation being so central to cryptography, the CMVP makes the use of an entropy source that has been evaluated according to the NIST Entropy Source Validation (ESV) program a requirement.

Key Points:

Random number generation being so central to cryptography, the CMVP makes the use of an entropy source that has been evaluated according to the NIST Entropy Source Validation (ESV) program a requirement.
ID Quantique is proud to announce that its Quantis QRNG chips product range has just received ESV certification on the Independent and Identically Distributed (IID) entropy estimation track.
This certificate provides the assurance that a particular entropy source conforms to NIST SP 800-90B and IDQ's QRNG chips fully meet these requirements.
ID Quantique is the first company to achieve an ESV certificate with a quantum-based entropy source and IID estimation track.

ID Quantique's range of Quantum Random Number Generator (QRNG) chips are the first quantum-based RNGs's to receive NIST Entropy Source Validation (ESV) Certification on IID Track

Retrieved on:

Wednesday, September 20, 2023

Random number generation being so central to cryptography, the CMVP makes the use of an entropy source that has been evaluated according to the NIST Entropy Source Validation (ESV) program a requirement.

Key Points:

Random number generation being so central to cryptography, the CMVP makes the use of an entropy source that has been evaluated according to the NIST Entropy Source Validation (ESV) program a requirement.
ID Quantique is proud to announce that its Quantis QRNG chips product range has just received ESV certification on the Independent and Identically Distributed (IID) entropy estimation track.
This certificate provides the assurance that a particular entropy source conforms to NIST SP 800-90B and IDQ's QRNG chips fully meet these requirements.
ID Quantique is the first company to achieve an ESV certificate with a quantum-based entropy source and IID estimation track.

IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024

Retrieved on:

Thursday, September 14, 2023

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2024, which ended July 31, 2023.

Key Points:

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2024, which ended July 31, 2023.
“We are immensely proud to share that ImmunoPrecise Antibodies has commenced fiscal year 2024 with unparalleled vigor and determination.
Company demonstrates record quarterly revenue, an increase of 21.3% compared to the same quarter last year.
Significantly higher net income before taxes when compared to Q1 of last year, a difference of approximately $6 million dollars, another positive back-to-back quarter trend.

Transamerica Taps Industry Leader Pooja Rahman as Chief Risk Officer

Retrieved on:

Monday, September 11, 2023

BALTIMORE, Sept. 11, 2023 /PRNewswire/ -- Transamerica announced today that Pooja Rahman will be appointed as Chief Risk Officer (CRO) and a member of the Transamerica Management Board, effective September 11, 2023.

Key Points:

BALTIMORE, Sept. 11, 2023 /PRNewswire/ -- Transamerica announced today that Pooja Rahman will be appointed as Chief Risk Officer (CRO) and a member of the Transamerica Management Board, effective September 11, 2023.
Her responsibilities will include managing all risk and actuarial functions along with maintaining Transamerica's risk management framework and enhancing its risk management capabilities.
Ms. Rahman joins Transamerica from Dai-ichi Life Holdings, Inc.'s US subsidiary Protective Life Corporation, where she has served as Chief Risk Officer.
Ms. Rahman succeeds Julie Spore, who has served as Chief Risk Officer since 2019, and will remain with the company in a new senior leadership position.

What Happens if You Get a DUI for the First Time in Florida?

Retrieved on:

Tuesday, September 5, 2023

Ignition, Administrative License Suspension, IID, DUI, Arrest, BAC, Ignition interlock device, Substance abuse, Ridesharing, Practice of law, Nursing

ORLANDO, Fla., Sept. 5, 2023 /PRNewswire/ -- In Florida, the penalties for a first-time misdemeanor DUI conviction are varied and can include:

Key Points:

In some cases, you may be eligible for a hardship license that allows you to drive to certain locations like work or school.
Fines: Fines range from $500 to $1,000, depending on the circumstances of the offense.
Possible Imprisonment: While jail time is uncommon for a first-time DUI offense, it is a possibility, especially if aggravating factors are involved.
These penalties can vary based on factors such as BAC level, prior criminal history, and other circumstances surrounding your arrest.

Ormat Technologies’ Arrowleaf Solar and Storage Facility Secures Long-Term PPA with San Diego Community Power

Retrieved on:

Wednesday, July 5, 2023

Ormat Technologies, IID, Electricity, Imperial Irrigation District, ORA, Investment, Growth, NYSE, Renewable energy

Ormat, a leading renewable energy company, and SDCP, California’s second largest community choice aggregator, signed a power purchase agreement for the Arrowleaf Solar and Storage Facility demonstrating their collective commitments to delivering clean and reliable energy solutions.

Key Points:

Ormat, a leading renewable energy company, and SDCP, California’s second largest community choice aggregator, signed a power purchase agreement for the Arrowleaf Solar and Storage Facility demonstrating their collective commitments to delivering clean and reliable energy solutions.
“We are excited to partner with San Diego Community Power on the Arrowleaf Solar and Storage Facility,” said Doron Blachar, CEO of Ormat Technologies.
Under the terms of the 20-year contract, Ormat will provide SDCP with sustainable electricity generated by the Arrowleaf Solar and Storage Facility at predictable rates for customers.
“San Diego Community Power’s mission is to provide clean, reliable, and affordable energy to our customers across the region,” said San Diego City Councilmember Joe LaCava, Chair of San Diego Community Power.

IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)

Retrieved on:

Tuesday, June 13, 2023

Apps, Applications, Technology, Infectious Diseases, Clinical Trials, Health Technology, Software, Biotechnology, Health, Data Management, Artificial Intelligence, IID, Research, AI, Medical imaging, Pharmaceutical industry

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration Dilemma (IID) solution developed by its subsidiary, BioStrand®.

Key Points:

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration Dilemma (IID) solution developed by its subsidiary, BioStrand®.
"Our newest use case stands as a potent testament to how we've successfully navigated the IID.
It demonstrates the power of integrating and organizing heterogeneous data types and reflects depth of insights gleamed using our comprehensive knowledge graph.
The unveiling of this use case is a testament to ImmunoPrecise's commitment to innovation and its dedication to solving complex problems in the field of biotechnology.